Cycl2r, your three-activity framework is accurate as far as it goes, and the question of whether there is a fourth layer, direct tumor cell destruction independent of immune priming, has a published answer worth giving you.
The short version: leronlimab does not kill tumor cells directly as a standalone cytotoxic agent. But it does something distinct from the three activities you named, and it matters.
The longer version follows.
Your three-activity framework maps correctly onto the literature.
Anti-metastatic activity is documented in the Jiao, Wang, and Pestell 2021 Breast Cancer Research paper, showing greater than 98 percent reduction in TNBC lung metastasis in xenograft models through CCR5-dependent blockade of tumor cell extravasation and distant seeding.
Anti-fibrotic activity is documented across three independent mouse models in the Palmer et al. hepatic fibrosis publication, with p-values of 0.0005, less than 0.0001, and 0.0006.
PD-L1 upregulation is documented in cell culture, histology, and Rhesus monkey models from the AACR IO February 2026 presentation by Professor Jiao, with leronlimab-mediated CCR5 inhibition increasing PD-L1 and PD-1 abundance and reducing sB7-H3 and sTyro3 immune suppression mediators simultaneously.
The fourth activity layer is chemotherapy and radiation sensitization, and it is distinct from immune priming.
At the AACR Special Conference in Brain Cancer in March 2026 https://www.reddit.com/r/Livimmune/comments/1..._abstract/ , the poster presented by Ritika Harish documented that CCR5 inhibition with leronlimab demonstrated functional synergy with temozolomide, enhancing tumor cell killing in human GBM cell lines, and that pretreatment with leronlimab enhanced radiation-induced cytotoxicity. Metabolic profiling using Seahorse analysis showed that CCR5 inhibition reduced oxygen consumption rate in a dose-dependent manner, consistent with modulation of glycolytic and metabolic programs. This is not immune architecture manipulation. This is direct interference with the metabolic machinery the tumor cell uses to sustain proliferation and resist DNA damage.
The Jiao 2021 paper confirms the same pattern in TNBC: leronlimab alone did not cause significant cytotoxicity in breast cancer cell lines, but the addition of leronlimab to doxorubicin decreased cell viability and enhanced cell death across seven cell lines at p less than 0.001. The mechanism is CCR5-dependent disruption of the proliferative signaling cascade, confirmed in the June 2026 Frontiers in Immunology phosphoproteomics paper showing CCR5 knockout abolishing CEP131, KHDRBS1, and MAPK6 activation, all of which are cell cycle regulators. When those pathways are disrupted simultaneously with DNA-damaging chemotherapy or radiation, the tumor cell's repair and survival machinery is compromised at two levels at once.
So the complete framework has four confirmed activity layers: anti-metastatic through CCR5-dependent blockade of tumor cell extravasation; anti-fibrotic through CCR5-dependent stellate cell and myeloid trafficking suppression; immune priming through PD-L1 upregulation and T cell exhaustion pathway modulation; and chemotherapy and radiation sensitization through CCR5-dependent metabolic and cell cycle disruption. The fourth layer does not replace the immune priming argument. It operates alongside it and means leronlimab's contribution to tumor killing is not entirely dependent on having a functional immune system present to do the downstream work.
That is a meaningfully broader platform than three activities alone, and you identified the right question to ask.
The short version: leronlimab does not kill tumor cells directly as a standalone cytotoxic agent. But it does something distinct from the three activities you named, and it matters.
The longer version follows.
Your three-activity framework maps correctly onto the literature.
Anti-metastatic activity is documented in the Jiao, Wang, and Pestell 2021 Breast Cancer Research paper, showing greater than 98 percent reduction in TNBC lung metastasis in xenograft models through CCR5-dependent blockade of tumor cell extravasation and distant seeding.
Anti-fibrotic activity is documented across three independent mouse models in the Palmer et al. hepatic fibrosis publication, with p-values of 0.0005, less than 0.0001, and 0.0006.
PD-L1 upregulation is documented in cell culture, histology, and Rhesus monkey models from the AACR IO February 2026 presentation by Professor Jiao, with leronlimab-mediated CCR5 inhibition increasing PD-L1 and PD-1 abundance and reducing sB7-H3 and sTyro3 immune suppression mediators simultaneously.
The fourth activity layer is chemotherapy and radiation sensitization, and it is distinct from immune priming.
At the AACR Special Conference in Brain Cancer in March 2026 https://www.reddit.com/r/Livimmune/comments/1..._abstract/ , the poster presented by Ritika Harish documented that CCR5 inhibition with leronlimab demonstrated functional synergy with temozolomide, enhancing tumor cell killing in human GBM cell lines, and that pretreatment with leronlimab enhanced radiation-induced cytotoxicity. Metabolic profiling using Seahorse analysis showed that CCR5 inhibition reduced oxygen consumption rate in a dose-dependent manner, consistent with modulation of glycolytic and metabolic programs. This is not immune architecture manipulation. This is direct interference with the metabolic machinery the tumor cell uses to sustain proliferation and resist DNA damage.
The Jiao 2021 paper confirms the same pattern in TNBC: leronlimab alone did not cause significant cytotoxicity in breast cancer cell lines, but the addition of leronlimab to doxorubicin decreased cell viability and enhanced cell death across seven cell lines at p less than 0.001. The mechanism is CCR5-dependent disruption of the proliferative signaling cascade, confirmed in the June 2026 Frontiers in Immunology phosphoproteomics paper showing CCR5 knockout abolishing CEP131, KHDRBS1, and MAPK6 activation, all of which are cell cycle regulators. When those pathways are disrupted simultaneously with DNA-damaging chemotherapy or radiation, the tumor cell's repair and survival machinery is compromised at two levels at once.
So the complete framework has four confirmed activity layers: anti-metastatic through CCR5-dependent blockade of tumor cell extravasation; anti-fibrotic through CCR5-dependent stellate cell and myeloid trafficking suppression; immune priming through PD-L1 upregulation and T cell exhaustion pathway modulation; and chemotherapy and radiation sensitization through CCR5-dependent metabolic and cell cycle disruption. The fourth layer does not replace the immune priming argument. It operates alongside it and means leronlimab's contribution to tumor killing is not entirely dependent on having a functional immune system present to do the downstream work.
That is a meaningfully broader platform than three activities alone, and you identified the right question to ask.
11
